Analysts expect 60 Degrees Pharmaceuticals, Inc. to report revenue of 280,068.30 for Q3 26, against a range of 267,214.01 to 292,922.59. The most recent reported quarter, Q2 26, came in at 207,900.00, a 16.4% beat against the 178,670.22 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 135,000.00 | 230,000.00 | 163,600.00 | 305,000.00 | 500,000.00 | 310,000.00 | 230,000.00 | 207,900.00 | - | - | - | - | - | - | - | - | ||||||
| High Estimate | 254,320.54 | 269,400.59 | 331,739.07 | 335,982.02 | 217,650.71 | 363,187.91 | 436,310.05 | 187,566.03 | 292,922.59 | 337,560.24 | 412,389.99 | 569,470.16 | 615,633.78 | 566,096.33 | 369,071.52 | 488,437.27 | ||||||
| Low Estimate | 213,576.96 | 248,449.41 | 303,222.93 | 278,849.98 | 203,589.29 | 315,154.49 | 401,713.11 | 169,774.41 | 267,214.01 | 296,476.56 | 356,422.01 | 500,069.84 | 530,310.22 | 482,637.07 | 304,832.32 | 415,027.17 | ||||||
| Consensus Estimate | 233,948.75 | 258,925.00 | 317,481.00 | 307,416.00 | 210,620.00 | 339,171.20 | 419,011.58 | 178,670.22 | 280,068.30 | 317,018.40 | 384,406.00 | 534,770.00 | 572,972.00 | 524,366.70 | 336,951.92 | 451,732.22 |
Analysts expect 60 Degrees Pharmaceuticals, Inc. to report earnings per share of -0.58 for Q3 26, against a range of -0.61 to -0.55. The most recent reported quarter, Q2 26, came in at -0.90, a 15.4% miss against the -0.78 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -18.60 | -9.18 | -6.24 | -4.82 | -2.67 | -1.69 | -1.28 | -0.90 | - | - | - | - | - | - | - | - | ||||||
| High Estimate | -12.37 | -14.03 | -4.98 | -4.41 | -1.61 | -1.33 | -0.68 | -0.74 | -0.55 | -0.61 | -0.81 | -0.87 | 1.69 | 2.45 | -1.55 | -2.11 | ||||||
| Low Estimate | -14.01 | -15.85 | -5.76 | -5.05 | -1.85 | -1.43 | -0.80 | -0.82 | -0.61 | -0.67 | -0.91 | -0.95 | 1.43 | 2.19 | -1.69 | -2.45 | ||||||
| Consensus Estimate | -13.19 | -14.94 | -5.37 | -4.73 | -1.73 | -1.38 | -0.74 | -0.78 | -0.58 | -0.64 | -0.86 | -0.91 | 1.56 | 2.32 | -1.62 | -2.28 |
Pull Wall Street consensus for 60 Degrees Pharmaceuticals, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=SXTP&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "SXTP", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=SXTP&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();